DR. ALLAN LANDRITO official webiste
STATEMENT OF THE ANTI-RED TAPE AUTHORITY ON FDA’S ISSUANCE OF LTO TO IVERMECTIN COMPOUNDER DR. ALLAN LANDRITO
Following our insistent calls to expedite the processing of permit applications, the Anti-Red Tape Authority (ARTA) is pleased to learn that the Food and Drug Administration (FDA) has issued a License to Operate (LTO) for medicine trading to Dr. Allan Landrito, a vocal proponent of using Ivermectin to treat COVID-19.
ARTA was informed about this a day after the regulatory body announced on Thursday the granting of a Compassionate Special Permit (CSP) to a hospital to use the abovementioned experimental drug on COVID-19 patients.
Dr. Landrito received his two-year LTO on 8 April 2021 allowing him, thru his Health and Wellness Products Trading, to be exporter of own products, importer of finished pharmaceutical products locally repacked/packed, importer of raw materials for own use, and wholesaler of own products.
With the LTO also, Dr. Landrito’s drug trading firm is now qualified to “apply for a market authorization [i.e. registration (CPR) or notification] for health products prior to manufacture, importation, sale or offer for sale, distribution, transfer and advertisment” before the FDA.
Therefore, this gives him a chance to finally seek a Compassionate Special Permit (CSP) or a Certificate of Product Registration (CPR) for Ivermectin, which he previously admitted compounding for his patients with COVID-19.
Late last March, ARTA Director General Jeremiah Belgica called for hearings to tackle complaints of several individuals and groups from the medical field, including Dr. Landrito, against the FDA over the slow resolution of their permit applications.
After thorough deliberations, DG Belgica asked the FDA to be pro-active and assist Dr. Landrito in his LTO application since the matters that have been holding it up are just minor details that may be easily resolved.
ARTA will be keeping an eye on all applications with FDA specially those relating to drugs and devices that are essential during this pandemic.
Among the pending requests for licenses at FDA is for Certificate of Product Registration (CPR) of Lloyd Laboratories for Ivermectin as an anti-parasitic medication.